SCHEMBL6465

SCHEMBL6465

Cc1ccc(Br)cc1S(=O)(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 2/20 0.45
EDNRA P25101 2/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43
ESR2 Q92731 1/20 0.43
ALDH1A1 P00352 1/20 0.39
IDH1 O75874 3/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
CA12 O43570 2/20 0.37
CA9 Q16790 2/20 0.37
AKR1C3 P42330 1/20 0.37
BRD4 O60885 1/20 0.37
TSHR P16473 1/20 0.37
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28847054 0.98 EDNRB (0.44) EDNRBEDNRAKMT2APOLBRECQL
SCHEMBL6012134 0.83 CA1 (0.49) EDNRBEDNRAKMT2AALDH1A1CA1
Hydrochloric Acid SCHEMBL27660485 0.82 CA1 (0.47) EDNRBEDNRAKMT2AALDH1A1CA1
SCHEMBL9196907 0.81 EDNRB (0.46) EDNRBEDNRAKMT2AALDH1A1IDH1
SCHEMBL265203 0.81 EDNRB (0.46) EDNRBEDNRAKMT2AALDH1A1CA1
SCHEMBL264948 0.79 EDNRB (0.45) EDNRBEDNRAKMT2AALDH1A1IDH1
SCHEMBL1346608 0.79 CA2 (0.49) EDNRBEDNRAKMT2AALDH1A1CA1
SCHEMBL8984847 0.79 KMT2A (0.42) EDNRBEDNRAKMT2AALDH1A1IDH1
SCHEMBL11330232 0.79 EDNRB (0.42) EDNRBEDNRAKMT2AALDH1A1IDH1
SCHEMBL196908 0.78 S100A4 (0.48) ESR2CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117209760-B Sulfonated benzimidazole polymer and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2024-03-12 CN disclosed
CN-117209760-A Sulfonated benzimidazole polymer and preparation method and application thereof 国家电投集团氢能科技发展有限公司 2023-12-12 CN disclosed
US-7533978-B2 Color composition and inkjet recording method FUJIFILM CORPORATION (JP) 2009-05-19 US disclosed
US-7533978-B2 Color composition and inkjet recording method FUJIFILM CORPORATION (JP) 2009-05-19 US disclosed
US-7297696-B2 Antagonists of MCP-1 function and methods of use thereof TELIK, INC. (US) 2007-11-20 US disclosed
EP-1383757-B1 ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF TELIK INC (US) 2006-09-27 EP disclosed
US-6998407-B2 Antagonists of MCP-1 function and methods of use thereof TELIK, INC. (US) 2006-02-14 US disclosed
US-6992086-B2 Antagonists of MCP-1 function and methods of use thereof TELIK, INC. (US) 2006-01-31 US disclosed
EP-1363897-B1 ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF TELIK INC (US) 2005-12-21 EP disclosed
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof LABORDE EDGARDO (US) 2005-03-10 US disclosed
WO-1996028425-A1 PIPERIDINYL-2-ALKYL SUBST. LINEAR POLYAMINES FOR THE REDUCTION OF INTRACELLULAR, ENDOGENIC POLYAMINE LEVELS SUCH AS PUTRESCINE, SPERMIDINE AND SPERMINE, AND THEIR IMPACT ON CELL PROLIFERATION NOVARTIS AG (CH) 1996-09-19 WO disclosed
WO-1996022979-A1 IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS S-ADENOSYLMETHIONINE DECARBOXYLASE (=SAMDC) INHIBITORS NOVARTIS AG (CH) 1996-08-01 WO disclosed
WO-1996016980-A1 MORPHOLINOETHYLAMIDE DERIVATIVES NOVARTIS AG (CH) 1996-06-06 WO disclosed
EP-0708760-A1 CYCLIC HYDRAZINE COMPOUNDS Novartis AG (CH) 1996-05-01 EP disclosed
WO-1995002582-A1 CYCLIC HYDRAZINE COMPOUNDS CIBA-GEIGY AG (CH) 1995-01-26 WO disclosed
US-4598076-A 2-pyrrolin-3-carbonitril-derivatives, pharmaceutical compositions containing them and their anti-inflammatory and ulcer protective activity WARNER-LAMBERT COMPANY (US) 1986-07-01 US disclosed
US-4517185-A 2-Pyrrolin-3-carbonitrile derivatives, and pharmaceutical compositions containing them and their anti-inflammatory and ulcer protective activity WARNER-LAMBERT COMPANY (US) 1985-05-14 US disclosed
US-4208351-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1980-06-17 US disclosed
US-4176233-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1979-11-27 US disclosed
US-4102902-A Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor ELI LILLY AND COMPANY (US) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 EDNRB 56/4885EDNRA 60/4885KMT2A 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.